Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxel-cisplatin combination chemotherapy: single institution experience

Kocak M., Mayadagli A. , Ozkan A., Parlak C., Demir O., Marti A., ...Daha Fazla

JOURNAL OF BUON, cilt.12, sa.4, ss.471-476, 2007 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Konu: 4
  • Basım Tarihi: 2007
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.471-476


Purpose: Despite advances in the detection and treatment, the long-term survival of patients with advanced non-small cell lung cancer (NSCLC) remains poor, with a 5-year overall survival (OS) of less than 5%. We conducted this observational study to determine the influence of docetaxel plus cisplatin combination chemotherapy on response, time to progression (TTP) and OS, and to evaluate its tolerability in chemotherapy-naive patients with metastatic NSCLC.